ArticlePloS one2015
Serum IgE Induced Airway Smooth Muscle Cell Remodeling Is Independent of Allergens and Is Prevented by Omalizumab.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 57 citations in OpenAlex.
- Trial
- Airway structural involvement detected by quantitative computed tomography in controlled and uncontrolled asthma.BMC pulmonary medicine · 2026Observational
- Biologics and airway remodeling in asthma: early, late, and potential preventive effects.Allergy · 2025Review
- Airway remodelling in asthma and the epithelium: on the edge of a new era.The European respiratory journal · 2024Review
- The Incredible Adventure of Omalizumab.International journal of molecular sciences · 2024Review
- Pulmonary inflammation and fibroblast immunoregulation: from bench to bedside.The Journal of clinical investigation · 2023Review
- Epithelial-Mesenchymal Transition Mechanisms in Chronic Airway Diseases: A Common Process to Target?International journal of molecular sciences · 2023Review
- Long non coding RNAs reveal important pathways in childhood asthma: a future perspective.Journal of molecular histology · 2023Review
- Biologics and airway remodeling in severe asthma.Allergy · 2022Review
- Asthma remission: what is it and how can it be achieved?The European respiratory journal · 2022Review
- Research advances in airway remodeling in asthma: a narrative review.Annals of translational medicine · 2022Review
- The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review.Biomedicines · 2021Review
- Immunologic Pathophysiology and Airway Remodeling Mechanism in Severe Asthma: Focused on IgE-Mediated Pathways.Diagnostics (Basel, Switzerland) · 2021Review
- The Role of Atopy in COPD and Asthma.Frontiers in medicine · 2021Review
- Status and prospects: personalized treatment and biomarker for airway remodeling in asthma.Journal of thoracic disease · 2020Review
- Immunologic and Non-Immunologic Mechanisms Leading to Airway Remodeling in Asthma.International journal of molecular sciences · 2020Review
- Biological Therapies of Severe Asthma and Their Possible Effects on Airway Remodeling.Frontiers in immunology · 2020Review
- IgE-mediated mast cell activation promotes inflammation and cartilage destruction in osteoarthritis.eLife · 2019Article
- IgE Downregulates PTEN through MicroRNA-21-5p and Stimulates Airway Smooth Muscle Cell Remodeling.International journal of molecular sciences · 2019Article
- Omalizumab and unmet needs in severe asthma and allergic comorbidities in Japanese children.Asia Pacific allergy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAirway wall remodeling in allergic asthma is reduced after treatment with humanized anti-IgE-antibodies. We reported earlier that purified IgE, without the presence of allergens, is sufficient to induce airway wall remodeling due to airway smooth muscle cell (ASMC) activity deposing extracellular matrix.
objectiveWe postulate that IgE contained in serum of allergic asthma patients, in the absence of allergens, stimulates ASMC remodeling activities and can be prevented by anti-IgE antibodies.
methodsIsolated human ASMC were exposed to serum obtained from: (i) healthy controls, or patients with (ii) allergic asthma, (iii) non-allergic asthma, and (iv) atopic non-asthma patients. Proliferation and the deposition of collagens and fibronectin were determined after 3 and 5 days.
resultsSerum from patients with allergies significantly stimulated: (i) ASMC proliferation, (ii) deposition of collagen type-I (48 hours) and (iii) of fibronectin (24 hours). One hour pre-incubation with Omalizumab prevented these three effects of allergic serum, but had no significant effect on serum from healthy donors or non-allergic asthma patients. Interestingly, the addition of allergens did not further increase any of the IgE effects. CONCLUSION AND CLINICAL RELEVANCE: Our data provides experimental evidence that the beneficial effect of Omalizumab on airway wall remodeling and improved lung function may be due to its direct action on IgE bound ASMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.